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Summary
Background.  —  Owing  to  the  wide  variety  of  surgical  substrates  used  for  right  ventricular  outﬂow
tract (RVOT)  reconstruction,  the  predictors  of  successful  outcomes  in  such  patients  are  unclear.
Aims. —  To  compare  haemodynamic  outcomes  of  percutaneous  pulmonary  valve  implantation
(PPVI) in  patients  with  dysfunctional  RVOT.
Abbreviations: Ao, aortic; BMS, bare-metal stent; PA, pulmonary artery; PPVI, percutaneous pulmonary valve insertion; RV, right
ventricle/ventricular; RVOT, right ventricular outﬂow tract; RV-PA, right ventricle to pulmonary artery; TR, tricuspid regurgitation.
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Methods.  —  This  was  a  multicentre  prospective  study  on  all  consecutive  patients  who  underwent
PPVI from  May  2008  to  December  2009.  All  patients  underwent  prestenting  using  a  bare-metal
stent. The  patients  were  divided  into  two  groups  based  on  the  surgical  substrate  used  for  RVOT
reconstruction.
Results. —  Baseline  demographics,  including  right  ventricle  to  pulmonary  artery  (RV-PA)  pressure
gradient  and  RV/aortic  (Ao)  pressure  ratio,  were  similar  in  both  groups.  The  mean  RV-PA  gradient
and RV/Ao  pressure  ratio  showed  immediate  and  signiﬁcant  improvement  after  PPVI.  At  last
follow-up,  the  RV-PA  gradient  and  RV/Ao  pressure  ratio  were  signiﬁcantly  higher  in  patients
with non-expandable  conduits  (P  =  0.002  and  P  =  0.008,  respectively).  Patients  with  conduits
greater  than  20  mm  showed  better  immediate  and  midterm  outcomes  compared  with  other
patients. Patients  with  non-expandable  conduits  less  or  equal  to  20  mm  diameter  showed  good
immediate  outcomes  but  poor  midterm  haemodynamic  outcomes  compared  with  those  with
expandable  conduits  less  or  equal  to  20  mm  diameter  (P  =  0.03).
Conclusions.  —  PPVI  is  successful  with  a  wide  variety  of  surgical  substrates  used  for  RVOT  recon-
struction;  there  was  immediate  haemodynamic  improvement  in  all  patients.  However,  patients
with non-expandable  conduits  less  or  equal  to  20  mm  had  the  worst  outcomes.  This  information
should be  integrated  into  the  decision-making  process  before  selecting  patients  for  PPVI.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — Il  existe  une  grande  variété  de  conduits  chirurgicaux  utilisés  pour  reconstruire  la
voie d’éjection  droite.  Lorsqu’ils  sont  potentiellement  candidats  à  la  mise  en  place  d’une  valve
par voie  percutanée,  les  facteurs  prédictifs  de  succès  ne  sont  aujourd’hui  pas  clairs.
Objectifs.  — Le  but  de  l’étude  est  de  comparer  les  résultats  hémodynamiques  après  valvulation
endovasculaire  pulmonaire  en  fonction  du  type  de  conduits  prothétiques.
Méthodes.  — Il  s’agit  d’une  étude  multicentrique,  prospective  regroupant  tous  les  patients
inclus consécutivement  entre  mai  2008  et  décembre  2009.  Tous  les  patients  ont  eu  un  pré-
stenting avant  la  mise  en  place  de  la  valve  par  voie  percutanée.  Les  patients  ont  été  divisés
en deux  groupes  selon  le  type  de  conduit  chirurgical  mis  en  place  pour  reconstruire  la  voie
d’éjection  droite.
Résultats.  — L’hémodynamique  de  base  comprenant  le  gradient  entre  le  ventricule  droit  et
l’artère pulmonaire,  le  rapport  pression  ventriculaire  droite  sur  pression  aortique  systolique,
était similaire  dans  les  deux  groupes.  Après  valvulation,  il  y  avait  une  amélioration  immédiate  de
ces paramètres.  Au  dernier  suivi,  le  gradient  entre  le  ventricule  droit  et  l’artère  pulmonaire,  le
rapport pression  ventriculaire  droite  sur  pression  aortique  systolique  étaient  signiﬁcativement
plus élevés  chez  les  patients  ayant  des  conduits  non  dilatables  (p  =  0,002  et  p  =  0,008,  respec-
tivement).  Les  patients  avec  un  conduit  de  diameter  nominal  supérieur  à  20  mm  avaient  un
meilleur devenir  à  court  et  moyen  terme  par  rapport  aux  autres.  Les  patients  avec  un  conduit
non expansible  de  moins  de  20  mm  avaient  un  bon  devenir  à  court  terme  mais  un  résultat  hémo-
dynamique médiocre  à  moyen  terme  lorsqu’ils  étaient  comparés  aux  patients  avec  des  conduits
expansibles  de  moins  de  20  mm  (p  =  0,03).
Conclusions.  —  Le  remplacement  valvulaire  percutané  est  efﬁcace  chez  des  patients  ayant  eu
une reconstruction  de  la  voie  d’éjection  droite  avec  une  grande  variété  de  conduits  chirurgi-
caux. Il  était  noté  une  amélioration  de  l’hémodynamique  immédiate  chez  tous  les  patients  quel
que soit  le  type  de  conduit  chirurgical  en  place.  Cependant,  les  patients  avec  des  conduits  non
expansibles  de  moins  de  20  mm  avaient  des  résultats  médiocres  à  moyen  terme.  Cette  infor-
mation doit  être  intégrée  dans  la  prise  de  decision  lors  de  la  selection  des  patients  pour  une
implantation  percutanée  d’une  valve  pulmonaire.
.  Tou
B
P
c
w
V
a
c
r
t
a
t
c© 2012  Elsevier  Masson  SAS
ackground
ercutaneous  pulmonary  valve  replacement  using  the  trans-
atheter  technique  has  been  widely  accepted  and  practiced
orldwide.  The  device  (Melody® Transcatheter  Pulmonary
alve;  Medtronic  Inc.,  Minneapolis,  MN,  USA)  is  available  in
 single  diameter  of  18  mm,  dilatable  up  to  22  mm.  The  indi-
ations  are  currently  limited  to  patients  with  dysfunctional
r
t
ns  droits  réservés.
ight  ventricular  outﬂow  tract  (RVOT)  homografts  or  pros-
hetic  conduits  with  a  diameter  that  does  not  exceed  22  mm
t  the  time  of  implantation  [1—4]. Surgical  techniques
o  maintain  right  ventricle  to  pulmonary  artery  (RV-PA)
ontinuity  can  be  achieved  by  modiﬁcation  of  RVOT  or
econstruction  using  a  variety  of  biological  or  synthetic
ubes;  these  are  available  in  various  sizes  as  expandable  or
on-expandable  conduits.  Owing  to  wide  variations  in  the
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re-metal stent; PPVI: percutaneous pulmonary valve insertion.
Table  1 Classiﬁcation  of  right  ventricular  reconstruc-
tion  conduits  used  in  the  study  population.
Expandable  Non-expandable
Native  RVOT  enlarged  with
a  patch
Synthetic  non-expandable
conduits
Native  RVOT  enlarged  with
a  Monocusp
Dacron  valved  conduits
Synthetic  expandable
conduits  (Contegra)
Hancock  conduits
Homograft  Carpentier-Edwards
conduits
RVOT: right ventricular outﬂow tract. Contegra (Medtronic,
Minneapolis, MN, USA); Dacron valved conduits (DuPont, Wil-
mington, DE, USA); Hancock conduits (Medtronic, Minneapolis,
MN, USA); Carpentier-Edwards conduits (Edwards Lifesciences,
Irvine, CA, USA).
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surgical  substrates  used  for  RVOT  reconstruction,  the  out-
comes  after  percutaneous  pulmonary  valve  insertion  (PPVI)
may  vary  and  are  presently  unclear.  We  sought  to  evalu-
ate  the  immediate  and  midterm  haemodynamic  outcomes
of  PPVI  in  patients  with  expandable  versus  non-expandable
conduits.
Methods
This  is  a  prospective  multicentre  non-randomized  trial  to
evaluate  outcomes  after  Melody® valve  implantation  in
France  (Y.  B.  principal  investigator).  The  study  received
approval  from  the  French  Ministry  of  Health  in  May  2008.
Patients  with  pulmonary  regurgitation  and/or  stenosis  were
enrolled  in  four  different  centres  across  France  (Paris,  Massy,
Marseille  and  Bordeaux).  Patients  with  dysfunctional  RVOT
were  identiﬁed  and  evaluated  to  assess  suitability  for  PPVI.
All  patients  were  evaluated  using  a  standard  protocol  to
assess  procedural  success,  complications,  costs,  safety  and
immediate  and  midterm  outcomes.  This  is  an  ongoing  study
and  the  global  results  are  still  pending.  We  report  outcomes
on  all  patients  who  underwent  PPVI  from  May  2008  to  Decem-
ber  2009  in  two  centres  (Centre  de  Reference  Maladies  Rares
M3  C,  George  Pompidou  European  Hospital  [adult  unit]  and
Necker  Hospital  [children  unit],  Paris,  France,  operator  Y.B.;
and  Timone  Hospital,  Marseille,  operator  A.F.).  The  study
is  registered  at  the  National  Institute  of  Health  website
(www.clinicaltrials.gov)  as  identiﬁer  NCT01250327.Preprocedure evaluation
All  patients  underwent  a  preinclusion  clinical  evaluation,
including  electrocardiography,  echocardiography,  exercise
t
c
p
pesting,  computed  tomography  scan  and  magnetic  reso-
ance  imaging.  Qualifying  patients  had  varying  RVOT  lesion
haracteristics,  such  as  pulmonary  obstruction,  pulmonary
egurgitation  and  mixed  lesions  [3].  Patients  with  obstruc-
ion  or  mixed  lesions  were  included  in  this  study.  Medical
harts  were  reviewed  to  assess  the  details  of  the  RV-PA
onduit.  The  study  population  was  divided  into  two  groups
ith  respect  to  the  expandable  characteristics  of  the  ini-
ial  conduit:  group  I  consisted  of  patients  with  expandable
onduits;  group  II  consisted  of  patients  with  non-expandable
rosthetic  conduits  (Fig.  1  and  Table  1).  The  grouping  was
erformed  by  two  authors  blinded  to  the  outcome.  The
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lassiﬁcation  was  made  based  on  the  intrinsic  properties  of
he  initial  conduit  and  not  on  the  properties  after  in  vivo
xposure;  therefore,  features  such  as  calciﬁcations,  exter-
al  compressions,  etc.  were  not  taken  into  account  for
lassiﬁcations.
ardiac catheterization and sizing of the RVOT
ll  patients  underwent  cardiac  catheterization  using  general
naesthesia  or  deep  sedation  with  or  without  endotracheal
entilation.  A  preprocedure  detailed  haemodynamic  assess-
ent  was  done  in  all  patients,  with  assessment  of  mean
ight  atrial,  RV  (systolic,  early  and  end-diastolic),  PA  and
ortic  (Ao)  pressures  (systolic,  diastolic  and  mean).  The
eak-to-peak  RV-PA  gradient  was  calculated  as  the  differ-
nce  in  systolic  pressure  between  the  RV  chamber  and  the
ain  PA.  If  the  RV/Ao  systolic  pressure  ratio  was  greater
han  0.66,  stenosis  was  the  primary  indication.  If  the  RV/Ao
ystolic  pressure  ratio  was  less  than  0.25  in  the  presence  of
ulmonary  regurgitation,  pulmonary  regurgitation  was  con-
idered  the  primary  lesion.  The  remainder  were  categorized
s  mixed  lesions.  Patients  with  regurgitation  as  the  primary
esion  were  excluded  from  this  study.  RVOT  and  aortic  root
ngiograms  were  performed  in  two  views  (lateral  and  four-
hamber)  in  all  patients.  Ao  angiography  was  performed  to
ssess  the  proximity  of  the  Melody® valve  landing  zone  to
he  coronary  arteries.
reparation for Melody® valve insertion
ll  patients  had  prestenting  of  the  RVOT  using  single  or  mul-
iple  bare-metal  stents  (BMSs)  (CP,  [NuMED,  Hopkinton,  NY,
SA]  or  Max  LD  [EV3,  Plymouth,  MN,  USA]).
elody® valve insertion
he  Melody® valve  (Model  PB10)  was  inserted  using  the  22-
m  Ensemble® transcatheter  valve  delivery  system  (NU10)
Medtronic  Inc.,  Minneapolis,  MN,  USA).  All  patients  under-
ent  RVOT  predilatation  with  a  balloon  of  appropriate
iameter  (ATLAS® or  Mullins  PTA  Dilatation  Balloon;  Bard
eripheral  Vascular,  Inc.,  Tempe,  AZ,  USA)  before  Melody®
alve  implantation.  The  diameter  of  the  balloon  was  equal
o  the  nominal  conduit  size  (maximum  diameter  22  mm).
alloons  were  inﬂated  to  the  burst  pressure  indicated  on
he  manufacturer’s  label,  regardless  of  the  grouping.  In
atients  with  no  circumferential  conduit  (patch  enlarge-
ent),  a  PTA  Dilatation  Balloon  22  mm  in  diameter  was
sed.  Postdilatation  was  achieved  using  a  high-pressure
alloon  in  all  patients,  with  the  aim  of  decreasing  the
VOT  gradient  as  much  as  possible.  Therefore,  overexpan-
ion  above  the  nominal  conduit  size  was  performed  when
eeded.  Haemodynamic  and  angiographic  assessments  were
epeated  after  PPVI  in  all  patients.  All  patients  received
eparin  and  antibiotic  prophylaxis  during  and  after  the
rocedure,  according  to  institutional  protocol,  and  were
ischarged  on  aspirin  100  mg/day  orally.ollow-up
ll  patients  were  scheduled  for  an  ofﬁce  visit  at  1,  3,  6,
2  and  24  months  following  valve  implantation.  A  repeat
m
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ransthoracic  echocardiogram  was  performed  during  every
ollow-up.  All  events  were  recorded  in  a  large  institutional
eview  board-approved  database.
tatistical analysis
ASW  Statistics  version  17.0  (SPSS,  Inc.,  Chicago,  IL,
SA)  was  used  for  statistical  analysis.  Nominal  varia-
les  are  expressed  as  numbers  and  percentages  and  were
ompared  using  Fisher’s  exact  test  or  the  chi-square
est,  as  appropriate.  Ordinal  variables  are  presented  as
eans  ±  standard  deviations  and  were  compared  using  the
ilcoxon  rank  sum  test.  Continuous  variables  are  expressed
s  means  ±  standard  deviations  and  were  compared  using
he  independent  variables  t test.  All  tests  were  two-sided
nd  a  P  value  <  0.05  was  considered  statistically  signiﬁcant.
esults
ifty-two  consecutive  patients  who  underwent  Melody®
alve  implantation  at  two  centres  (Necker/George  Pompi-
ou  [n  =  44];  Marseille  [n  =  8])  from  May  2008  to  December
009  were  included  in  this  study.  There  were  20  children  (i.e.
ged  below  18  years)  and  32  adults  (mean  age,  22.7  ±  9.18
ears;  median  age,  22.2  years  [10.6—54.8  years]).  Forty-one
atients  were  aged  above  15  years.  There  were  33  patients
n  group  I  (expandable)  and  19  patients  in  group  II  (non-
xpandable).  Angiographic  views  in  each  group  are  given  in
igs.  2—4.
Basal  haemodynamic  characteristics,  such  as  RV-PA  gra-
ient  and  RV/Ao  pressure  ratio,  were  similar  in  both
roups.  The  mean  RV-PA  gradient  and  RV/Ao  pressure  ratio
howed  immediate  and  signiﬁcant  improvement  after  PPVI,
egardless  of  the  substrate  or  size.  The  improvement  was,
owever,  more  pronounced  in  patients  with  expandable
ompared  with  non-expandable  conduits  (12.9  ±  6.6  mmHg
s  19.7  ±  7.9  mmHg  [P  =  0.002];  and  0.4  ±  0.1  vs  0.5  ±  0.1
P  =  0.008])  (Table  2).
The  mean  follow-up  duration  was  similar  in  both  the
roups  (511.8  ±  288.6  days  vs  491.32  ±  229  days;  P =  0.7).
roup  I  showed  better  outcomes  until  the  last  follow-up.
o  stent  fracture  was  observed  in  any  group.
Further  stratiﬁcation  of  each  group  based  on  the  prePPVI
iameter  of  the  RVOT  conduit  showed  varying  outcomes.
 cutoff  of  20  mm  was  found  and  used  for  subdividing
ach  group.  Group  II  subgroups  (group  IIA:  less  or  equal  to
0  mm  [n  =  9];  group  IIB:  greater  than  20  mm  [n  =  10])  showed
he  following  results:  both  subgroups  showed  similar  basal
haracteristics  and  immediate  haemodynamic  improvement
Table  3).  However,  at  last  follow-up,  RV  systolic  pres-
ure  measured  by  tricuspid  regurgitation  jet  showed  poor
aemodynamic  outcomes  in  subgroup  IIB  compared  with  sub-
roup  IIA  (75.8  ±  36.9  mmHg  vs  41.5  ±  8.5  mmHg;  P  =  0.006).
Group  I  subgroups  (group  IA:  less  or  equal  to  20  mm
n  =  15];  group  IB:  greater  than  20  mm  [n  =  18])  showed
he  following  results:  both  subgroups  showed  similar  basal
haracteristics  and  immediate  haemodynamic  improve-
ent  (Table  4).  However,  at  last  follow-up,  RV  systolic
ressure  showed  poor  haemodynamic  outcomes  in  sub-
roup  IB  compared  with  subgroup  IA  (47.9  ±  21.9  mmHg  vs
6.8  ±  4.5  mmHg;  P  =  0.005).
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Figure 2. Angiographic views showing a patient with a non-expandable conduit following insertion of a Melody® valve. A. Still frame
without dye showing the Melody® valve securely ﬁxed by the existence of a metallic ring around the right ventricular outﬂow tract conduit,
limiting its expansion. B. Excellent function of the inserted valve: no leak on angiography. Note the space between the ring and the stent
related to the fabric of the prosthetic conduit.
Figure 3. Angiographic views showing a patient with a non-expandable conduit at various stages of a Melody® valve implantation. A.
Angiographic view at the beginning of the procedure showing a stenotic extra-anatomic right ventricular outﬂow tract Gore-Tex conduit.
B and C. Angiographic views showing the results after opening with multiple bare-metal stents and insertion of the Melody® valve. The
expansion of the stents remains limited.
Figure 4. Angiographic views showing a patient with an expandable conduit (homograft) at various stages of a ®Melody valve implantation.
A. Angiographic view at the beginning of the procedure showing a stenotic homograft. B and C. Angiographic views showing the results after
prestenting and insertion of the Melody® valve. The stents are fully expanded and valve function is excellent.
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Table  2  Comparative  haemodynamic  outcomes  after  percutaneous  pulmonary  valve  insertion  in  patients  with  pre-
existing  expandable  versus  non-expandable  right  ventricular  outﬂow  tract  conduits.
Expandable  conduits
(n  =  33)
Non-expandable
conduits  (n  =  19)
P
Basal  RV-PA  systolic  gradient  (mmHg)  50.9  ±  23.1  57.3  ±  22.9  0.33
Basal  RV/Ao  pressure  ratio  0.9  ±  0.15  0.81  ±  0.2  0.16
Immediate  post-Melody® RV-PA  gradient  (mmHg)  12.9  ±  6.6  19.7  ±  7.9  0.002
Immediate  post-Melody® RV/Ao  pressure  ratio  0.4 ±  0.1  0.5 ±  0.1  0.008
RV  systolic  pressure  at  last  follow-up  (mmHg) 40.4 ± 2.1  68.2 ±  35.6  0.003
Ao: aortic; PPVI: percutaneous pulmonary valve insertion; RV: right ventricle; RVOT: right ventricular outﬂow tract; RV-PA: right ventricle
to pulmonary artery.
Table  3 Comparative  haemodynamic  outcomes  after  percutaneous  pulmonary  valve  insertion  in  patients  with  pre-
existing  non-expandable  right  ventricular  outﬂow  tract  conduits  less  or  equal  to  20  mm  and  greater  than  20  mm  in
diameter.
Non-expandable
conduits  ≤  20  mm
Subgroup  IIA  (n  =  9)
Non-expandable
conduits  >  20  mm
Subgroup  IIB  (n  =  10)
P
Basal  RV-PA  systolic  gradient  (mmHg)  59.1  ±  24.1  50.5  ±  19  0.4
Basal  RV/Ao  pressure  ratio  0.9  ±  0.2  0.8  ±  0.1  0.3
Immediate  post-Melody® RV-PA  gradient  (mmHg)  20.7  ±  8.2  15.5  ±  5.9  0.25
Immediate  post-Melody® RV/Ao  pressure  ratio  0.5  ±  0.2  0.5  ±  0.6  0.4
RV  systolic  pressure  at  last  follow-up  (mmHg)  75.8  ±  36.9  41.5  ±  8.5  0.006
Ao: aortic; PPVI: percutaneous pulmonary valve insertion; RV: right ventricle; RVOT: right ventricular outﬂow tract; RV-PA: right ventricle
to pulmonary artery.
Table  4  Comparative  haemodynamic  outcomes  after  percutaneous  pulmonary  valve  insertion  in  patients  with  pre-
existing  expandable  right  ventricular  outﬂow  tract  conduits  less  or  equal  to  20  mm  and  greater  than  20  mm  in  diameter.
Expandable
conduits  ≤  20  mm
Subgroup  IA  (n  =  15)
Expandable
conduits  >  20  mm
Subgroup  IB  (n  =  18)
P
Basal  RV-PA  gradient  (mmHg) 57.7 ± 21.2  45.3  ±  16.01  0.7
Basal  RV/Ao  pressure  ratio  0.89  ±  0.2  0.8  ±  0.1  0.5
Immediate  post-Melody® RV-PA  gradient  (mmHg)  14.4  ±  9.1  11.6  ±  5.3  0.35
Immediate  post-Melody® RV/Ao  pressure  ratio  0.4  ±  0.2  0.4  ±  0.6  0.6
RV  systolic  pressure  at  last  follow-up  (mmHg) 47.9  ±  21.9  36.8  ±  4.5  0.005
Ao: aortic; PPVI: percutaneous pulmonary valve insertion; RV: right ventricle; RVOT: right ventricular outﬂow tract; RV-PA: right ventricle
to pulmonary artery.
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rComparative  haemodynamic  outcomes  after  PPVI  in
atients  with  pre-existing  expandable  and  non-expandable
VOT  conduits  ≤  20  mm  in  diameter  showed  poor  outcomes
or  non-expandable  conduits  compared  with  expandable
onduits  (Table  5).
iscussionercutaneous  pulmonary  valve  replacement  using  the  trans-
atheter  technique  for  approved  indications  is  becoming
tandard  practice  worldwide.  The  technique  using  the
r
i
p
aelody® valve  is  presently  limited  to  patients  with  dysfunc-
ional  prosthetic  conduits  or  homografts  with  a  diameter
hat  does  not  exceed  22  mm  at  the  time  of  implantation
1—4].  RV-PA  continuity  can  be  achieved  surgically  by  using
arious  tubes:  expandable  conduits  and  non-expandable
ynthetic  conduits.  As  such,  candidates  for  percutaneous
ulmonary  valve  replacement  are  heterogeneous  with
espect  to  the  type  of  surgical  RVOT  reconstruction  and  the
esults  may  thus  differ  accordingly.  Outcomes  after  PPVI
n  patients  with  homografts  may  not  be  the  same  as  in
atients  with  prosthetic  conduits.  In  our  centre,  the  avail-
bility  of  homografts  is  low,  making  prosthetic  conduits  the
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Table  5  Comparative  haemodynamic  outcomes  after  percutaneous  pulmonary  valve  insertion  in  patients  with  pre-
existing  expandable  and  non-expandable  right  ventricular  outﬂow  tract  conduits  less  or  equal  to  20  mm  in  diameter.
Expandable
conduits  ≤  20  mm
Subgroup  IA  (n  =  15)
Non-Expandable
conduits  ≤  20  mm
Subgroup  IIA  (n  =  9)
P
Basal  RV-PA  gradient  (mmHg) 57.7 ±  21.2  59.1  ±  24.1  0.9
Basal  RV/Ao  pressure  ratio 0.89 ±  0.2  0.9 ±  0.2  0.9
Immediate  post-Melody® RV-PA  gradient  (mmHg)  14.4 ±  9.1  20.7 ±  8.2  0.1
Immediate  post-Melody® RV/Ao  pressure  ratio  0.4 ±  0.2  0.5 ±  0.2  0.2
RV  systolic  pressure  at  last  follow-up  (mmHg)  47.9  ±  22  75.8  ±  36.9  0.03
Ao: aortic; PPVI: percutaneous pulmonary valve insertion; RV: right ventricle; RVOT: right ventricular outﬂow tract; RV-PA: right ventricle
to pulmonary artery.
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Aﬁrst  choice  in  most  instances.  Our  goal,  therefore,  was  to
compare  the  haemodynamic  results  of  PPVI  in  patients  with
expandable  versus  non-expandable  conduits.
The  results  of  the  current  study  show  the  universal  efﬁ-
cacy  of  PPVI  in  all  types  of  RVOT  reconstruction,  at  least
up  to  midterm.  The  diameter  of  the  conduits  did  not  play
a  role  in  RVOT  obstruction  relief  as  long  as  the  surgical
substrates  were  homografts  or  patch  enlargement.  These
surgical  substrates  can  be  expanded  and  possibly  overex-
panded  at  or  above  their  nominal  diameter,  with  resultant
loss  of  RV-PA  gradient.  However,  results  are  worst  in  patients
with  non-expandable  prosthetic  conduits,  especially  when
size  is  taken  into  account.  Many  factors  can  be  implicated
to  explain  these  results.  Firstly,  by  deﬁnition,  conduits  with
armatures  or  non-expandable  material  such  as  Dacron  have
lower  distensibility  than  homografts;  this  is  compounded  by
exuberant  pannus  formation  on  the  prosthetic  conduit  over
time.  Prestenting  with  a  BMS  has  been  recommended  to  limit
the  risk  of  stent  fractures  [5,6]. However,  this  was  suggested
and  demonstrated  in  a  cohort  of  patients  with  homografts  as
RVOT  substitutes.  In  patients  with  non-expandable  conduits,
the  BMS  struts  would  encroach  the  RVOT  lumen,  causing  fur-
ther  narrowing;  this  may  explain  the  poor  haemodynamic
outcomes  in  such  patients.  Prestenting  is  likely  to  be  very
useful  in  patients  with  dynamic  RVOT  motion  and/or  extrac-
ardiac  compression  from  neighbouring  structures—factors
that  may  lead  to  Melody® valve  stent  fracture  and  poor  out-
comes.  The  BMS  struts  form  a  good  platform  for  scaffolding
of  tissue  in  the  preparation  of  a  stable  landing  zone  for  the
Melody® valve.
The  results  of  this  study  compel  the  interventionalist  to
strongly  consider  the  type  and  size  of  surgical  substrate  used
for  RVOT  modiﬁcation  or  reconstruction.  According  to  our
study  results,  the  patient  subsets  that  derive  the  highest
beneﬁt  from  PPVI  are,  in  descending  order:  patients  with
expandable  conduits  regardless  of  conduit  size;  patients
with  non-expandable  conduits  of  diameter  greater  than
20  mm  at  time  of  insertion;  patients  with  non-expandable
conduits  less  or  equal  to  20  mm  at  time  of  insertion.  In
the  second  and  third  subsets,  the  decision  about  prestent-
ing  should  be  weighed  against  potential  late  lumen  loss  and
worsening  RV  haemodynamics  with  time.
The  quest  for  a  better  substrate  for  PPVI  continues  as
we  adapt  to  current  technology.  What  is  an  ideal  sub-
strate?  In  our  opinion  there  is  no  clear  answer.  Both  types
T
(
Pf substrates  have  drawbacks  and  advantages.  We  believe
hat  non-expandable  conduits  offer  a  safer  landing  zone  for
elody® valve  insertion,  with  less  risk  of  stent  fractures.
owever,  their  use  limits  the  capability  of  stent  expansion,
specially  when  the  inner  diameter  is  less  than  20  mm.  In
omparison,  expandable  conduits  have  greater  expansion
apabilities  but  an  increased  risk  of  stent  movement  and
racture.  It  is  important  to  understand  the  natural  history
f  homografts  and  prosthetic  conduits  and  their  degenera-
ion  with  time,  to  answer  this  question.  If  calciﬁc  process
s  implicated,  the  replacement  conduit  should  be  as  large
s  possible  to  reduce  the  RVOT  gradient  and  improve  long-
erm  outcomes.  The  option  of  PPVI  by  the  transcatheter
echnique  is  always  available,  even  in  such  cases.  A  smaller
onduit  is  probably  indicated  to  offer  the  possibility  of  trans-
atheter  valve  implantation  but  we  do  not  recommend  this
pproach  as  technology  is  rapidly  evolving.  What  is  true
oday  may  not  be  true  tomorrow  with  new  devices  with
arger  diameters.
onclusion
PVI  is  feasible,  safe  and  successful  in  patients  with  the
ide  variety  of  surgical  substrates  used  for  RVOT  reconstruc-
ion.  There  was  immediate  haemodynamic  improvement
n  all  patients.  Patients  with  expandable  RVOT  conduits
howed  better  haemodynamic  outcomes  then  those  with
on-expandable  prosthetic  conduits,  regardless  of  conduit
iameter.  Patients  with  non-expandable  RVOT  prosthetic
onduits  ≤  20  mm  diameter  showed  poor  midterm  results.
his  information  needs  to  be  integrated  into  the  decision-
aking  process  before  selecting  patients  for  PPVI.
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